Skip to content
Use case 145

Clinical Trial Data Capture Terminals

A deployment concept for pharmaceutical companies, research sites, CROs and regulators.

Proposed deployment · Compatibility assessment required
Healthcare and Life Sciences

Why this environment matters

For clinical trial data capture terminals, the system records participant visits, outcomes, adverse events and protocol compliance. The risk extends beyond a conventional endpoint: altered timestamps, unauthorised edits or endpoint compromise can undermine trial integrity and regulatory submissions. A NØNOS deployment concept would treat every software component, data source and device interface as separately authorised rather than assuming that anything running on the host should be broadly trusted.

The security challenge

Healthcare systems process deeply sensitive data while supporting time-critical clinical decisions. Security must improve trust without delaying care or obscuring the human responsibility for treatment. In clinical trial data capture terminals, the decisive risk is that altered timestamps, unauthorised edits or endpoint compromise can undermine trial integrity and regulatory submissions. Even strong perimeter controls may not help once authorised software, a vendor tool or a valid user session has been compromised. Internal permission boundaries must remain enforceable after initial access.

How the capsule model could help

For this system, NØNOS could separate data entry, source-document viewing, query resolution and investigator sign-off with auditable, signed components. The design would combine patient-context capabilities, signed clinical software, isolated medical file parsers and minimal sensitive persistence. The intended result would be a set of small trust boundaries instead of one large operating environment where every service inherits broad ambient access.

Separate address spaces and capability checks can limit cross-process reach. They cannot stop harmful use of legitimate permissions, prove AI decisions correct or substitute for domain-specific safety controls.

Deployment requirements

Clinical deployment would require medical-device validation, patient-safety risk management, privacy review, human factors testing and integration with existing approved workflows. Security controls must never obstruct emergency care.

Current public-beta limitations, hardware support and application availability must be assessed before any pilot. Neither this use case nor an industry source establishes NONOS certification or a current customer deployment.

Who could buy or integrate it?

  • Clinical research sponsors purchasing trial data-entry environments
  • Electronic data capture vendors integrating site-facing clients
  • Contract research organisations managing study-terminal deployments

Industry examples: Medidata Solutions, Veeva Systems. Organisations shown illustrate the industry. No NONOS customer, partner or endorsement relationship is implied.

Market opportunity

Market benchmarks and device scenarios.

Published industry benchmark
US$2.1 billion

Electronic data capture systems

Global · 2025 · annual market estimate

EDC software and services for clinical research across trial phases and delivery models.

Modelled global devices
40K–800K

Candidate OS endpoints

Hypothetical planning range · 2025

Low confidence: planning assumptions. Hardware compatibility, procurement and adoption have not been validated.

Illustrative annual licensing
$2.4M–$176M

USD / year at full model coverage

Device scenario × assumed US$60–$220 per device / year.

Not a revenue forecast, announced price or measured serviceable market.

Device calculation

Hypothetical global planning range, 2025 scenario: assume 20,000–100,000 clinical trial sites and research coordination centers × 2–8 candidate OS endpoints per site/asset = 40,000–800,000 endpoints. Counting unit: study data-capture and monitoring terminals; each trial not a device. Site and asset counts, and devices per site, are planning assumptions. The installed base has not been measured. Coverage is limited to the defined equipped subset; includes all candidate endpoints within that assumed subset. Hardware eligibility, certification, adoption and achievable NØNOS share are unverified; overlaps other cases.

Electronic Data Capture Systems Market Size Report, 2026-2033 ↗

Market context only; separate from device and site population estimates. Original monetary-market scope and geography are preserved in benchmark. This source does not establish the assumed worldwide site count or endpoint density.

How to interpret the figures

Adjacent or broader commercial market benchmark; not the NØNOS OS market, licensable-device count or revenue forecast.

Modelled candidate endpoints multiplied by an assumed annual USD price per endpoint. Pricing is a planning assumption, not a vendor quote. This illustrates the full scenario range, not revenue or total addressable market. It excludes adoption timing, procurement, certification, support costs, channel economics and achievable market share. Use cases can overlap, so their totals do not represent unique devices.

Research from 2026. Publisher estimates have not been independently audited.

Read the full methodology

Explore NONOS

Choose your
NONOS experience.

Discover the platform for your organisation or explore the software.

You can reopen this chooser from the footer at any time.